Tommaso Filippini1, Federico Zagnoli2, Matteo Bosi3, Maria Edvige Giannone4, Cristina Marchesi5, Marco Vinceti6. 1. Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. tommaso.filippini@unimore.it. 2. Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. federico.zagnoli@unimore.it. 3. Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. matteo.bosi@unimore.it. 4. Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. edvige.giannone@unimore.it. 5. Head Office, Direzione Generale, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. Cristina.Marchesi@ausl.re.it. 6. Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy and 3Department of Epidemiology, Boston University School of Public Health, Boston, MA, US. marco.vinceti@unimore.it.
Abstract
BACKGROUND AND AIM: The exact COVID-19 severity is still not well defined and it is hotly debated due to the a few methodological issues such as the uncertainties about the spread of the SARS-CoV-2 infection. METHODS: We investigated COVID-19 case-fatality rate and infection-fatality rate in 2020 in Italy, a country severely affected by the pandemic, basing our assessment on publicly available data, and calculating such measures during the first and second waves. RESULTS: We found that province-specific crude case-fatality rate in the first wave (February-July 2020) had a median value of 12.0%. Data about infection-fatality rate was more difficult to compute, due to large underestimation of SARS-CoV-2 infection during the first wave when asymptomatic individuals were very rarely tested. However, when using as a reference population-based seroprevalence data for anti-SARS-CoV-2 antibodies collected in May-July 2020, we computed an infection-fatality rate of 2.2%. During the second wave (Sep-Dec 2020), when SARS-CoV-2 testing was greatly increased and extended to many asymptomatic individuals, we could only compute a 'hybrid' case/infection-fatality rate with a value of 2.2%, similar to the infection-fatality rate of the first wave. CONCLUSIONS: Overall, this study allowed to assess the COVID-19 case- and infection-fatality rates in Italy before of variant spread and vaccine availability, confirming their high values compared with other airborne infections like influenza. Our findings for Italy were similar to those characterizing other Western European countries.
BACKGROUND AND AIM: The exact COVID-19 severity is still not well defined and it is hotly debated due to the a few methodological issues such as the uncertainties about the spread of the SARS-CoV-2 infection. METHODS: We investigated COVID-19 case-fatality rate and infection-fatality rate in 2020 in Italy, a country severely affected by the pandemic, basing our assessment on publicly available data, and calculating such measures during the first and second waves. RESULTS: We found that province-specific crude case-fatality rate in the first wave (February-July 2020) had a median value of 12.0%. Data about infection-fatality rate was more difficult to compute, due to large underestimation of SARS-CoV-2 infection during the first wave when asymptomatic individuals were very rarely tested. However, when using as a reference population-based seroprevalence data for anti-SARS-CoV-2 antibodies collected in May-July 2020, we computed an infection-fatality rate of 2.2%. During the second wave (Sep-Dec 2020), when SARS-CoV-2 testing was greatly increased and extended to many asymptomatic individuals, we could only compute a 'hybrid' case/infection-fatality rate with a value of 2.2%, similar to the infection-fatality rate of the first wave. CONCLUSIONS: Overall, this study allowed to assess the COVID-19 case- and infection-fatality rates in Italy before of variant spread and vaccine availability, confirming their high values compared with other airborne infections like influenza. Our findings for Italy were similar to those characterizing other Western European countries.
The COVID-19 pandemic is one of the greatest medical challenges of the last century (1), especially for the possible clinical presentation as a severe and life-threatening disease (2), with limited therapeutic options, and long-term sequelae (3-5). Since the beginning, attempts to control the pandemic spread relied on public health measures such as social distancing, contact tracing, use of face masks and other protective gears (like googles or face shields in health care settings), and lockdowns with limitations of population mobility (6-10). Still in recent months that vaccines are available, the presence of virus variants and the possibility of reinfection are of great concern (11-13).Italy was the first Western country severely hit by the pandemic, with a widespread population involvement, especially in the North of the country during the first wave (14). Factors associated with increased susceptibility to COVID-19 onset and severity, following the infection with SARS-CoV-2, have been shown to be male sex, and presence of a comorbidity such as hypertension, diabetes, cardiovascular disease, or chronic lung disease (15,16). Also, environmental factors may play a role increasing COVID-19 susceptibility and severity (17-21) as also reported in previous studies carried out in Northern Italy suggesting a positive association between air pollutant levels with both SARS-CoV-2 incidence and COVID-19 mortality (22-24).During the 2020, Italy experienced two pandemic waves. The first wave started with the first diagnosed case on February 20, 2020 and lasted till end of June 2020, leading to the implementation of a tight lockdown from March 8 to May 4, 2020 (6). After a brief summer period characterized by light restrictions due to the very low number of newly diagnosed cases, from September 2020 cases rapidly increased again, leading to a second, lighter lockdown from November 6, 2020 (25). Since begin of the vaccination campaign in a few subjects in December 27, 2020 and during the 2021, Italy has experienced a subsequent third wave in February-May 2021 and a fourth one in the most recent period, although the last ones have been largely mitigated by the growing number of vaccinated people (26).Due to lack of a large availability of SARS-CoV-2 swab tests during the first wave, SARS-CoV-2 infection testing was limited to subjects with symptoms potentially related to COVID-19 as well to health professionals (27-29). From the end of the first lockdown, availability of SARS-CoV-2 swab tests greatly increased and, therefore, testing has been extended to asymptomatic and pauci-symptomatic subjects (30). In particular, drive-through facilities have been implemented in several Italian cities with up to 1000 daily tests (31). For this reason, number of SARS-CoV-2 infections was certainly underestimated during the first wave (14), as also confirmed by the nationwide seroprevalence data made available by the National Institute of Statistics based on a population-based survey conducted in May-July 2020 (32). As consequence, there are uncertainties and controversies about the severity of COVID-19 and namely its case-fatality rate (number of COVID-19 deaths divided by COVID-19 cases, i.e. the symptomatic subjects diagnosed with the disease) and infection-fatality rate (number of deaths divided by overall number of cases of SARS-CoV-2 infection, i.e. including both symptomatic and asymptomatic subjects), due to methodological issues (33). Such issues include the censoring when the outcome is still unknown at the time of the investigation, the occurrence of ascertainment biases (34-36), especially the underestimation SARS-CoV-2 infection and COVID-19 incidence during an emergency situation as during the pandemic spread, and heterogeneity in classifying the outcome, i.e. COVID-19 related deaths (37-41).In this study, we aimed at assessing COVID-19 fatality rates in Italy, focusing on case-fatality and infection-fatality rates during the first and second waves on a provincial level during the first year of the COVID-19 pandemic, when neither virus variants were present in the country nor the vaccination campaign had started yet (42,43).
Methods
We downloaded publicly available COVID-19 data from the website of the Civil Protection Agency (44) and National Institute of Statistics (45), collecting daily data flow that Italian regions had to mandatorily provide with a provincial level of detail. In detail, we used the number of newly diagnosed infections with SARS-CoV-2 (corresponding to the new positive tests of infection based on quantitative reverse transcription polymerase chain reaction) and number of COVID-19 deaths in two time frames: from February 24-June 30, 2020 (first wave), and from September 1-December 31, 2020 (second wave). We also used data about anti-SARS-CoV-2 antibody seroprevalence recently made available at a provincial level by a survey carried out by the National Institute of Statistics in May-July 2020 (32). In order to take into account possible differences in time-frame between the first wave period and the seroprevalence survey, we also considered as alternative first wave period February 24-July 31, 2020.We calculated the province-specific case-fatality rate, also called ratio (34,46), for the first and second waves by dividing the number of deaths by the number of diagnosed positive cases in the two periods February 24-June 30 and February 24-July 31, 2020. We then calculated the province-specific infection-fatality rate (34) by dividing the number of deaths occurred during the first wave (February 24-June 30, 2020) by the estimated number of seroprevalent subjects using data of the National Institute of Statistics carried out in the period May-July 2020 (32). We eventually computed the rate between deaths and positive molecular tests during the September 1-December 31 period, that we called ‘case/infection-fatality rate’ due to the hybrid nature of such indicator, whose denominator included asymptomatic and symptomatic SARS-CoV-2 infected cases due to nationwide marked changes in testing availability and policy (14). All these estimates were crude, i.e. unadjusted for age and sex.Using data made publicly available by the European Center for Disease Control (ECDC), we also retrieved COVID-19 cases and deaths occurred in all European countries during the 2020, available on a weekly basis (47). As we did with Italian provinces, we calculated the case-fatality rate and the case/infection- fatality rate for the first and second waves, respectively. For this purpose, we considered as first wave the time from the beginning of the virus spread up to summer period (June 30, 2020) when cases waned in almost all countries (some countries experienced a unique wave in the 2020). The beginning of second wave was considered variable according to the raising of the curve up to the end of the year, generally January 1, 2021 based on the weekly availability of data (47).We also compared data of fatality rate of COVID-19 with seasonal flu. We retrieved data of flu cases through reports released by the National Institute of Health (48), while we used annual flu deaths available from the National Institute of Statistics (49). We excluded the most recent years, taking into account the influence of the COVID-19 pandemic in the circulation of other airborne infections (50).To investigate the relation between province-specific estimates, we used linear regression to fit a restricted cubic spline model with three knots at fixed percentiles (10th, 50th and 90th) of first wave distribution and weighted by the provincial population in 2020 (51). We used a multivariable model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident, available using 2011 census data of the National Institute of Statistics (51). We used the Stata statistical software (Version-17.0 Stata Corp., College Station-TX, 2021) for all analyses.
Results
Table 1 presents detailed information about number of cases and deaths divided by first and second waves along with seroprevalence data in the Italian provinces. In Italy, diagnosed cases and deaths during the first wave were 235,839 and 35,048, respectively. Corresponding values for the second wave were 1,808,260 cases and 40,392 deaths.
Table 1.
Number of SARS-CoV-2 cases, COVID-19 deaths, COVID-19 case-fatality rate (deaths/cases*100) in the first (1st) wave (February 24-June 30), and case/infection-fatality rate (deaths/cases*100) in the second (2nd) waves (September 30-December 31) in 2020 divided by province and region. SARS-CoV-2 seroprevalence (%) after the 1st wave (period May-July 2020) and infection-fatality rate (deaths/seroprevalents*100).
Region/Province
Population Jan 1, 2020
Cases 1st wave
Cases 2nd wave
Seroprev. (%)
Deaths 1st wave
Deaths 2nd wave
Case-fatality rate 1st wave
Infection-fatality rate 1st wave
Case/infection fatality rate 2nd wave
Aosta Valley
125501
1195
5771
3.72
145
239
12.1
3.1
4.1
Aosta
125501
1195
5771
3.72
145
239
12.1
3.1
4.1
Lombardy
10103969
91813
368273
7.35
16633
8321
18.1
2.2
2.3
Bergamo
1116384
14375
12873
24.3
3137
193
21.8
1.2
1.5
Brescia
1268455
15626
25468
7.63
2686
422
17.2
2.8
1.7
Como
603828
4093
29531
2.00
587
794
14.3
4.8
2.7
Cremona
358347
6612
7664
19.7
1130
123
17.1
1.6
1.6
Lecco
337087
2831
10303
6.66
481
236
17.0
2.1
2.3
Lodi
230607
3570
6936
7.10
679
140
19.0
4.1
2.0
Mantua
411062
3496
12260
6.57
684
288
19.6
2.5
2.3
Milan
3279944
24379
147720
3.95
4252
3197
17.4
3.3
2.2
Monza/Brianza
878267
5772
42090
4.52
979
895
17.0
2.5
2.1
Pavia
546515
5568
18869
5.95
1241
543
22.3
3.7
2.9
Sondrio
180941
1584
6954
5.30
212
201
13.4
2.2
2.9
Varese
892532
3907
47605
1.71
565
1289
14.5
3.7
2.7
Veneto
4907704
18937
227276
1.92
2028
4960
10.7
2.1
2.2
Belluno
201972
1191
13369
1.88
114
330
9.6
3.0
2.5
Padua
939672
3954
41651
2.32
318
608
8.0
1.5
1.5
Rovigo
233386
444
6932
2.39
36
204
8.1
0.6
2.9
Treviso
888309
2673
45715
1.89
322
783
12.0
1.9
1.7
Venice
851663
2682
35612
1.68
299
863
11.1
2.1
2.4
Verona
930339
5127
44073
2.23
586
1195
11.4
2.8
2.7
Vicenza
862363
2866
39924
1.33
353
977
12.3
3.1
2.4
Emilia-Romagna
4467118
28061
137052
2.90
4353
3431
15.5
3.4
2.5
Bologna
1017806
5229
32314
2.33
732
936
14.0
3.0
2.9
Ferrara
344840
1044
7886
0.72
173
222
16.6
7.0
2.8
Forlì-Cesena
394833
1740
10213
1.04
196
164
11.3
4.8
1.6
Modena
707292
3873
25945
1.10
480
601
12.4
6.2
2.3
Parma
453930
3657
8701
5.84
901
215
24.6
3.4
2.5
Piacenza
287236
4428
10187
9.54
956
252
21.6
3.5
2.5
Ravenna
389634
1030
11337
1.18
81
430
7.9
1.8
3.8
Reggio nell’Emilia
531751
4913
18248
4.45
581
306
11.8
2.5
1.7
Rimini
339796
2147
12221
2.79
253
305
11.8
2.9
2.5
Piedmont
4341375
30989
162730
3.45
4029
3537
13.0
2.7
2.2
Alessandria
419037
4063
13240
2.08
659
470
16.2
7.7
3.5
Asti
213216
1874
7960
2.13
249
217
13.3
5.5
2.7
Biella
174384
1046
5748
6.59
194
112
18.5
1.7
1.9
Cuneo
586568
2862
24081
0.87
373
494
13.0
7.3
2.1
Novara
368040
2792
12443
5.21
367
272
13.1
1.9
2.2
Turin
2252379
15889
87788
3.58
1844
1712
11.6
2.3
2.0
Verbano-Cusio-Ossola
157455
1140
5515
9.05
132
122
11.6
0.9
2.2
Vercelli
170296
1323
5955
3.52
211
138
15.9
3.5
2.3
Trentino-South Tyrol
1074819
7502
43303
3.19
693
1041
9.2
2.0
2.4
Bolzano
532080
2639
26559
2.95
288
504
10.9
1.8
1.9
Trento
542739
4863
16744
3.42
405
537
8.3
2.2
3.2
Friuli-Venezia Giulia
1211357
3308
45651
1.02
362
1426
10.9
2.9
3.1
Gorizia
139206
216
5904
0.12
5
104
2.3
-†
1.8
Pordenone
312619
702
9792
1.88
68
291
9.7
1.2
3.0
Trieste
233276
1393
9107
0.59
209
270
15.0
-†
3.0
Udine
526256
997
20848
0.93
80
761
8.0
1.6
3.7
Liguria
1543127
9473
46958
3.24
1563
1276
16.5
3.1
2.7
Genoa
835829
5573
29304
3.61
943
853
16.9
3.1
2.9
Imperia
213919
1494
4806
2.39
231
79
15.5
4.5
1.6
La Spezia
219196
860
7142
1.89
159
189
18.5
3.8
2.6
Savona
274183
1546
5706
3.83
230
155
14.9
2.2
2.7
Tuscany
3722729
9779
108429
0.90
1088
2491
11.1
3.3
2.3
Arezzo
341766
676
9779
1.23
47
168
7.0
1.1
1.7
Florence
1004298
3192
29864
0.53
401
839
12.6
7.5
2.8
Grosseto
220785
396
3708
1.18
28
73
7.1
1.1
2.0
Livorno
333509
477
8079
0.56
62
195
13.0
3.3
2.4
Lucca
388678
1351
11010
0.42
151
192
11.2
9.3
1.7
Massa and Carrara
193934
1051
6442
0.00
153
179
14.6
-‡
2.8
Pisa
422310
930
15667
1.55
91
341
9.8
1.4
2.2
Pistoia
293059
747
9640
0.96
76
199
10.2
2.7
2.1
Prato
258152
532
9790
1.02
47
203
8.8
1.8
2.1
Siena
266238
427
4450
2.17
32
102
7.5
0.6
2.3
Umbria
880285
1385
26064
0.67
80
530
5.8
1.4
2.0
Perugia
655403
1008
19843
0.71
51
369
5.1
1.1
1.9
Terni
224882
377
6221
0.55
29
161
7.7
2.4
2.6
Marches
1518400
6549
33194
2.59
987
720
15.1
2.5
2.2
Ancona
469750
1875
9711
2.16
218
185
11.6
2.1
1.9
Ascoli Piceno
206363
290
4790
4.95
12
125
4.1
0.1
2.6
Fermo
173004
473
4337
2.16
67
69
14.2
1.0
1.6
Macerata
312146
1154
7851
2.16
145
159
12.6
2.2
2.0
Pesaro and Urbino
357137
2757
6505
4.95
545
182
19.8
3.1
2.8
Lazio
5865544
8010
148533
1.00
863
2815
10.8
1.4
1.9
Frosinone
485241
663
12990
0.19
79
162
11.9
8.6
1.2
Latina
576655
607
13625
0.50
44
294
7.2
1.5
2.2
Rieti
154232
411
4565
3.00
41
149
10.0
0.9
3.3
Rome
4333274
5872
108988
1.05
672
2016
11.4
1.4
1.8
Viterbo
316142
457
8365
1.52
27
194
5.9
0.6
2.3
Abruzzo
1305770
3261
31124
1.29
461
794
14.1
2.7
2.6
Chieti
383189
818
6284
1.40
131
136
16.0
2.4
2.2
L’Aquila
296491
225
10604
0.54
11
350
4.9
0.7
3.3
Pescara
318678
1586
5447
1.69
239
116
15.1
4.4
2.1
Teramo
307412
632
8789
1.48
80
192
12.7
1.8
2.2
Molise
302265
426
5971
0.81
28
175
6.6
1.1
2.9
Campobasso
218679
364
3829
0.66
22
110
6.0
1.4
2.9
Isernia
83586
62
2142
1.19
6
65
9.7
0.6
3.0
Campania
5785861
4648
182462
0.89
517
2915
11.1
1.0
1.6
Avellino
413926
552
8289
0.00
62
143
11.2
-‡
1.7
Benevento
274080
209
4423
0.00
19
137
9.1
-‡
3.1
Caserta
922171
543
33741
1.48
53
540
9.8
0.4
1.6
Naples
3082905
2652
111294
1.04
314
1811
11.8
1.0
1.6
Salerno
1092779
692
24715
0.31
69
284
10.0
2.1
1.1
Apulia
4008296
4502
84951
0.88
566
2037
12.6
1.6
2.4
Bari
1249246
1491
33237
1.50
153
636
10.3
0.8
1.9
Barletta-Andria-Trani
388390
380
10058
0.77
66
295
17.4
2.2
2.9
Brindisi
390456
659
5795
0.85
67
100
10.2
2.0
1.7
Foggia
616310
1170
18639
1.02
161
655
13.8
2.6
3.5
Lecce
791122
521
6420
0.01
85
114
16.3
-†
1.8
Taranto
572772
281
10802
0.67
34
237
12.1
0.9
2.2
Basilicata
556934
400
10055
0.72
36
214
9.0
0.9
2.1
Potenza
360936
189
6739
0.83
27
156
14.3
0.9
2.3
Matera
195998
211
3316
0.50
9
58
4.3
0.9
1.7
Calabria
1924701
1179
22191
0.51
129
368
10.9
1.3
1.7
Catanzaro
354851
214
3134
0.40
31
49
14.5
2.2
1.6
Cosenza
700385
468
6676
0.78
48
176
10.3
0.9
2.6
Crotone
170718
119
2065
0.11
10
35
8.4
5.2
1.7
Reggio di Calabria
541278
294
8586
0.18
29
81
9.9
3.1
0.9
Vibo Valentia
157469
84
1730
1.12
11
27
13.1
0.6
1.6
Sicily
4968410
3056
89352
0.37
342
2390
11.2
1.9
2.7
Agrigento
429611
135
3651
0.19
24
107
17.8
3.0
2.9
Caltanissetta
260779
186
3733
0.00
18
81
9.7
-‡
2.2
Catania
1104974
779
26464
0.26
103
849
13.2
3.6
3.2
Enna
162368
438
2866
0.00
34
76
7.8
-‡
2.7
Messina
620721
474
10246
0.32
59
136
12.4
2.9
1.3
Palermo
1243328
500
24929
0.89
43
665
8.6
0.4
2.7
Ragusa
321215
87
6490
0.30
6
161
6.9
0.6
2.5
Siracusa
397037
321
5112
0.14
47
162
14.6
8.8
3.2
Trapani
428377
136
5861
0.00
8
153
5.9
-‡
2.6
Sardinia
1630474
1366
28920
0.50
145
712
10.6
1.8
2.5
Cagliari
430914
253
6573
0.38
19
161
7.5
1.2
2.4
Nuoro
206843
78
6055
0.24
12
123
15.4
2.4
2.0
Oristano
156078
61
2416
0.43
8
51
13.1
1.2
2.1
Sassari
489634
875
8997
0.78
90
247
10.3
2.4
2.7
South Sardinia
347005
99
4879
0.42
16
130
16.2
1.1
2.7
Italy
60244639
235839
1808260
2.49
35048
40392
14.9
2.2
2.2
†Provinces excluded due to implausible data of seroprevalences since the estimated number of seroprevalent subjects are less than the number of positive cases at the end of the first wave.
‡Provinces excluded due to missing/null data about seroprevalence.
Number of SARS-CoV-2 cases, COVID-19 deaths, COVID-19 case-fatality rate (deaths/cases*100) in the first (1st) wave (February 24-June 30), and case/infection-fatality rate (deaths/cases*100) in the second (2nd) waves (September 30-December 31) in 2020 divided by province and region. SARS-CoV-2 seroprevalence (%) after the 1st wave (period May-July 2020) and infection-fatality rate (deaths/seroprevalents*100).†Provinces excluded due to implausible data of seroprevalences since the estimated number of seroprevalent subjects are less than the number of positive cases at the end of the first wave.
‡Provinces excluded due to missing/null data about seroprevalence.National average seroprevalence was 2.49%, with the highest values in Bergamo (24.3%), Cremona (19.7%), and Piacenza (9.5%). Six provinces (Avellino, Benevento, Caltanissetta, Enna, Massa-Carrara and Trapani) reported null seroprevalence, while three provinces, Lecce, Gorizia and Trieste, showed extremely low and implausible seroprevalence rates. We considered these latter provinces as unwarranted outliers arising from a low and potentially highly biased participation in the survey since the estimated number of seroprevalent subjects is lower than the ascertained cases during the first wave. For this reason, we removed these provinces from the analyses concerning the infection-fatality rate.Figure 1 shows the case-fatality rate (from swab testing) and the infection-fatality rate (from seroprevalence data) in the first wave, and the case/infection-fatality rate (from swab testing) in the second wave across the Italian provinces. Overall in Italy, crude case-fatality rate was 14.9% for the first wave and 2.2% for the second wave, while the crude infection-fatality rate based on seroprevalence after the first wave was 2.2%. Province-specific values of case-fatality rate showed a median value of 12% (ranging from 2.3% in Gorizia to 24.6% in Parma), while the infection-fatality rate using seroprevalence data was much lower with a median value of 2.2%. During the second wave, SARS-CoV-2 testing greatly increased and was extended also to asymptomatic subjects, leading to a ‘mixed’ case/infection-fatality rate with median value of 2.2%, comparable to the infection fatality rate of 2.2% (Table 1).
Figure 1.
Crude case-fatality rate (deaths per 100 cases) for first wave (February 24-June 30, 2020), infection-fatality rate (deaths per 100 cases) after the first wave, and case/infection-fatality rate for the second (September 1-December 31, 2020) wave.
Crude case-fatality rate (deaths per 100 cases) for first wave (February 24-June 30, 2020), infection-fatality rate (deaths per 100 cases) after the first wave, and case/infection-fatality rate for the second (September 1-December 31, 2020) wave.In Table 2 we report SARS-CoV-2 cases and COVID-19 deaths occurred in European countries in 2020 divided in the two pandemic waves, and the case-fatality and case/infection-fatality rates in European countries for the first and second waves, respectively. Overall, Italy showed one of the highest first-wave case-fatality rate (14.43%) along with other severely hit countries such as France (18.22%), Belgium (15.48), and UK (14.15%) compared to the value of EE/EEA area (10.59%) (Table 2 and Figure 2). In the majority of European countries, the second wave began from August to mid-September 2020, with some exceptions reporting an earlier onset in July, namely France, Spain, Malta, and Ukraine, with consequent difficulties in the comparison. Overall in 2020, the EE/EEA area showed a fatality rate of 2.38%, with the highest values reported by Bulgaria (3.78%), Greece (3.54%), and Italy (3.49%).
Table 2.
Crude case-fatality (deaths per 100 cases) for the first (1st) wave for all EU/EEA countries (+ Switzerland and United Kingdom) from the beginning of the pandemic to June 30 if not differently specified, and case/infection-fatality rate (deaths per 100 cases) for the second (2nd) wave. Time-frame is different with the begin of the second wave indicated for each country, while the end was January 3, 2021 for all countries.
Country
Total population 2020†
Cases 1st wave
Deaths 1st wave
Case-fatality 1st wave
2nd wave time-frame
Cases 2nd wave
Deaths 2nd wave
Case/infection fatality 2nd wave
Total 2020 cases
Total 2020 deaths
2020 fatality
Andorra
76177
855
52
6.08
14 Sep
6848
31
0.45
8192
84
1.03
Austria
8901064
18269
706
3.86
14 Sep
331239
5497
1.66
364574
6253
1.72
Belgium
11522440
62394
9660
15.48
14 Sep
556759
9927
1.78
651968
19876
3.05
Bulgaria
6951482
5740
246
4.29
5 Oct
181464
6834
3.77
203051
7678
3.78
Croatia
4058165
3151
113
3.59
5 Oct
195299
3774
1.93
212958
4072
1.91
Cyprus
888005
1003
19
1.89
12 Oct
21988
106
0.48
23974
131
0.55
Czech Republic
10693939
12556
352
2.80
31 Aug
722615
12005
1.66
747003
12431
1.66
Denmark
5822763
12832
606
4.72
7 Sep
151164
747
0.49
168711
1374
0.81
Estonia
1328976
1993
63
3.16
23 Oct
25110
178
0.71
29521
251
0.85
Finland
5525292
7272
309
4.25
7 Sep
28628
289
1.01
36919
607
1.64
France
67320216
164068
29893
18.22
27 Jul
2457579
34845
1.42
2636772
65037
2.47
Germany
83166711
196554
9016
4.59
7 Sep
1524714
25249
1.66
1775513
34574
1.95
Greece
10718565
3519
192
5.46
10 Aug
134476
4745
3.53
140099
4957
3.54
Hungary
9769526
4183
589
14.08
31 Aug
322890
9363
2.90
328851
9977
3.03
Iceland
364134
1830
10
0.55
14 Sep
3589
19
0.53
5754
29
0.50
Ireland
4964440
25527
1741
6.82
7 Sep
72215
482
0.67
101887
2259
2.22
Italy
59641488
241611
34861
14.43
31 Aug
1887228
39855
2.11
2155446
75332
3.49
Latvia
1907675
1124
30
2.67
21 Sep
40972
644
1.57
42497
680
1.60
Liechtenstein
38747
84
1
1.19
5 Oct
2096
34
1.62
2222
35
1.58
Lithuania
2794090
1836
79
4.30
5 Oct
142802
1856
1.30
147987
1950
1.32
Luxembourg
626108
4522
110
2.43
14 Sep
39725
382
0.96
46919
506
1.08
Malta
514564
671
9
1.34
27 Jul
12520
208
1.66
13219
217
1.64
Monaco
39244
75
1
1.33
5 Oct
685
2
0.29
907
3
0.33
The Netherlands
17407585
50621
6127
12.10
31 Aug
750122
5383
0.72
820193
11598
1.41
Norway
5367580
8895
251
2.82
19 Oct
34579
171
0.49
50715
449
0.89
Poland
37958138
35950
1517
4.22
28 Sep
1235617
26729
2.16
1322947
29161
2.20
Portugal
10295909
43897
1614
3.68
7 Sep
371365
5356
1.44
431623
7196
1.67
Romania
19328838
28973
1750
6.04
21 Sep
527648
11544
2.19
640429
15979
2.50
San Marino
34453
698
42
6.02
12 Oct
1741
20
1.15
2493
62
2.49
Slovakia
5457873
1798
28
1.56
21 Sep
306848
2616
0.85
314117
2657
0.85
Slovenia
2095861
1700
111
6.53
7 Sep
122684
2761
2.25
125858
2891
2.30
Spain
47332614
251789
28388
11.27
6 Jul
1702891
22672
1.33
1958844
51078
2.61
Sweden
10327589
70612
5576
7.90
5 Oct
366858
4232
1.15
462661
10125
2.19
Switzerland
8606033
32184
1685
5.24
5 Oct
405397
5455
1.35
459660
7238
1.57
Ukraine
43733759
48500
1249
2.58
20 Jul
1015251
17369
1.71
1074093
18854
1.76
United Kingdom
68059863
287121
40632
14.15
7 Sep
2307627
33473
1.45
2654779
75024
2.83
EU/EEA countries
45309377
1264974
133967
10.59
-
-
-
-
15963232
379360
2.38
†
Population data from Eurostat (
Figure 2.
Map and histograms of case-fatality and case/infection-fatality during the first and second waves in EU/EEA countries (+ Switzerland and United Kingdom).
Crude case-fatality (deaths per 100 cases) for the first (1st) wave for all EU/EEA countries (+ Switzerland and United Kingdom) from the beginning of the pandemic to June 30 if not differently specified, and case/infection-fatality rate (deaths per 100 cases) for the second (2nd) wave. Time-frame is different with the begin of the second wave indicated for each country, while the end was January 3, 2021 for all countries.†
Population data from Eurostat (Map and histograms of case-fatality and case/infection-fatality during the first and second waves in EU/EEA countries (+ Switzerland and United Kingdom).In Table 3, we report data about cases of seasonal flu epidemics, and we computed an average case-fatality rate from past seasons of 0.01%, which is orders of magnitude lower of COVID-19 disease.
Table 3.
Number of influenza cases and deaths in Italy during the most recent seasonal flu epidemics.
Season
Flu cases
ISTAT report
Flu deaths
2012/2013
5995000
2013
417
2013/2014
4542000
2014
272
2014/2015
6299000
2015
675
2015/2016
4876900
2016
316
2016/2017
5440900
2017
663
2017/2018
8677300
2018
745
Number of influenza cases and deaths in Italy during the most recent seasonal flu epidemics.When we compared the case-fatality rate of the first wave with the infection-fatality rate after the first wave using seroprevalence data in the Italian provinces using the spline analysis (Figure 3), we found a substantially linear positive association up to approximately 12% of case-fatality rate in the first wave corresponding to 3.6 infection-fatality rate, while the curve flattened at higher values.
Figure 3.
Comparison of first wave case-fatality rate (using positive swab data to estimate COVID-19 cases) and infection-fatality rate (using May-June seroprevalence data to estimate infected cases) considering the time frames February 24-June 30, 2020 (A) and February 24-July 31, 2020 (B). Spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident.
Comparison of first wave case-fatality rate (using positive swab data to estimate COVID-19 cases) and infection-fatality rate (using May-June seroprevalence data to estimate infected cases) considering the time frames February 24-June 30, 2020 (A) and February 24-July 31, 2020 (B). Spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident.In the spline regression model comparing case-fatality rate in the first wave with the case/infection-fatality rate in the second wave, we did not find any relation between the two variables. On average, the case-fatality rate was 5.6 times 95% CIs (95% CI 5.2-6.1) higher in the first compared to the second wave (Figure 4).
Figure 4.
Comparison of first and second wave case-fatality rate in a spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident.
Comparison of first and second wave case-fatality rate in a spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident.
Discussion
At the end 2020, Italy was one of the countries reporting the highest number of confirmed positive cases as well as COVID-19 deaths (52). Since many uncertainties still exist about the real impact and severity of COVID-19 pandemic (33,37,53,54), in the present investigation we provided an assessment of the COVID-19 case-fatality and infection-fatality rates during the 2020 in Italian provinces.Overall, our data confirmed that during the first wave, when almost all subjects underwent SARS-CoV-2 testing due to presence of symptoms related to COVID-19, the Italian case-fatality rate was as high as around 15%, being much higher than the infection-fatality rate. Conversely, during the second wave, the case/infection fatality rate we could compute waned to a much lower value of 2.2%. The most plausible explanation for this discrepancy is the hybrid nature of the latter estimate, due to the different policy for SARS-CoV-2 infection assessment. In fact, during the first wave only suspected cases due to travelling from high risk countries or with symptoms suggesting of COVID-19 were tested (55), while during the second waves also asymptomatic cases underwent swab testing. These findings appear to be confirmed by the assessment of the infection-fatality rate estimated through seroprevalence data, almost identical to COVID-19 fatality during the second wave, with the same overall national value of 2.2%. In addition, the comparison of the COVID-19 fatality rates in other European countries demonstrated generally a higher case-fatality rate for Italy during the first wave, and a marked decrease during the second wave that could have been at least partially due to the increase of population screening with SARS-CoV-2 swab testing of a large proportion of asymptomatic individuals (55). However, since the availability of SARS-CoV-2 molecular testing increased all over Europe during the second wave, our results may also indicate that the severity of the disease and the spread of the infection decreased in Italy with time during 2020, as compared with the other European countries, for reasons possibly related to the higher severity of the first wave, such as a larger prevalence of immunity in the population, or the increased depletion of highly susceptible individuals due to the high first wave COVID-19 mortality (56-59).Interestingly, our results are partially conflicting with data from a recent meta-analysis suggesting much lower value (2.7%) during the first wave in European region (33) but higher estimates for Italy with a mean value of 7.8% (median=8.58%) and range from 1.7% up to 14.5%. This high heterogeneity could be explained by the modality of case-fatality assessment among different studies. In particular, the lower value was reported from a study implementing modelling techniques, e.g. SEIR (Susceptible-Exposed-Infective-Recovered) model (60), as well as when based on incomplete data when the first wave was still ongoing (61). Conversely, studies using real and comprehensive data demonstrated similar or even higher estimates compared with the present study (62-64). Interestingly, a comparable pattern of discrepancies in the estimation of case-fatality rate can be noted also for other countries severely hit by the pandemic such as United Kingdom and France (33). For these reasons, despite such modelling demonstrated a high reliability in the prediction of pandemic tend/curves (65,66), the estimation of disease case-fatality was not so effective and reliable, also since that the number of infections and deaths may be affected by other determinants, in particular the advances in SARS-CoV-2 infection as well as COVID-19 diagnosis (67), and especially treatment (68-70).The occurrence of a high case-fatality rate in Italy was not entirely unexpected, being explained by the demographic and health characteristics of the Italian population. Also, at the very beginning of the pandemic in Italy, a case-fatality rate of 7.2% was estimated by the National Institute of Health (71), much higher compared with the one reported in China (72). Indeed, COVID-19 demonstrated to be more severe and deadly in vulnerable individuals due to older age and/or comorbidities (73,74), leading to a higher mortality in older subjects (75). Similarly, our findings are consistent with the recent report of the National Institute of Statistics, as they found a slightly higher (sex and age-adjusted) case-fatality rate of 4.3% in the entire 2020 (52). Consistently with our findings, such analysis yielded a higher value in the first pandemic period (although based on a slightly different timeframe, February-May 2020), i.e. 6.6%, a lower value in June-September (1.5%), and again a slightly higher value in October (2.4%).Results of the seroprevalence nationwide survey confirmed that some Northern Italy areas were heavily affected during the first wave (76), especially the provinces of Bergamo, Brescia, Lodi, Cremona in Lombardy region, and Piacenza and Parma in Emilia-Romagna region (14). Such provinces were those that experienced the highest decrease in the hybrid case/infection fatality rate we could compute for the second wave, consistently with a pattern we have documented for COVID-19 incidence (14).Our results indicated that the case-fatality rate of COVID-19 was much higher as compared with influenza through 2020 and independently from the time period, indicating that COVID-19 should not be considered a simply flu-like syndrome (77,78), with much larger implications in terms of population and public health burden. This further confirms how relevant is the implementation of effective preventive medicine measures against SARS-CoV-2 infection and COVID-19 including but not limited to vaccination, also in the absence of most effective therapy for this disease (79). Finally, our findings are particularly relevant from a public health perspective since they highlight how different was the impact of the COVID-19 pandemic compared to the seasonal flu and other outbreaks, taking into account the number of affected people and deaths, the health care systems overload, and the psychological and economic burden (80-82).Our study has some limitations. First, we used aggregated data at a provincial level, showing much higher level of geographical detail than the previous ‘regional’ analyses but still not entirely homogeneous in terms of population size characteristics, despite we tried to control for some potential confounders. In addition, we could not calculate sex- and age-standardized estimates, and therefore the comparison across different geographical areas must be made with caution (83).Strengths of our analysis include the assessment of the COVID-19 severity during the first two pandemic waves when there was no circulation of virus variants (43), making unlikely this possible confounding related to differences in virus transmission and severity (84,85). Similarly, the vaccination campaign effectively began in January 2021 (86), thus not affecting the susceptibility of subjects and the reliability of our analysis.
Conclusions
Our findings demonstrate that COVID-19 severity in Italy, as assessed through either case-fatality or infection-fatality rates, has been much higher compared with other airborne infections like influenza, while being substantially similar to a few other Western European countries. They also indicate that COVID-19 case-fatality rate and infection fatality rate substantially differ, though such measures are difficult to assess, due to methodological issues and potential biases that can affect these estimates. An adequate assessment of COVID-19 severity may also be of major relevance to plan and test public health interventions aimed at curbing the spread of SARS-CoV-2 infection.
Authors: Manuel Battegay; Richard Kuehl; Sarah Tschudin-Sutter; Hans H Hirsch; Andreas F Widmer; Richard A Neher Journal: Swiss Med Wkly Date: 2020-02-07 Impact factor: 2.193
Authors: Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-05-29 Impact factor: 19.103
Authors: Daniela Calina; Anca Oana Docea; Demetrios Petrakis; Alex M Egorov; Aydar A Ishmukhametov; Alexsandr G Gabibov; Michael I Shtilman; Ronald Kostoff; Félix Carvalho; Marco Vinceti; Demetrios A Spandidos; Aristidis Tsatsakis Journal: Int J Mol Med Date: 2020-05-06 Impact factor: 4.101
Authors: Alberto Romagnolo; Roberta Balestrino; Gabriele Imbalzano; Giovannino Ciccone; Franco Riccardini; Carlo Alberto Artusi; Marco Bozzali; Bruno Ferrero; Elisa Montalenti; Elisa Montanaro; Mario Giorgio Rizzone; Giovanna Vaula; Maurizio Zibetti; Leonardo Lopiano Journal: J Neurol Date: 2020-08-04 Impact factor: 4.849
Authors: Antonio Vinci; Amina Pasquarella; Maria Paola Corradi; Pelagia Chatzichristou; Gianluca D'Agostino; Stefania Iannazzo; Nicoletta Trani; Maria Annunziata Parafati; Leonardo Palombi; Domenico Antonio Ientile Journal: Int J Environ Res Public Health Date: 2022-05-13 Impact factor: 4.614